With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Visterra has begun efforts to bounce back from its failed IPO attempt by securing a contract from CARB-X.

Blueprint Medicines has filed to raise $150 million to equip itself to take its phase 1 candidates deeper into development.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Ex-Pfizer exec is looking for new biopharma opportunities as Intrexon spins out all its healthcare programs into a new company.

As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…

Returns on R&D among the world's largest pharma companies are still in free fall with no signs of a recovery, says Deloitte.

Let’s be honest, 2016 was a mess of year, and one that many of us will be happy to see the back of. It saw the loss of a series of beloved actors, actresses…